These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32540349)

  • 1. A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization.
    Lanza JS; Vucen S; Flynn O; Donadei A; Cojean S; Loiseau PM; Fernandes APSM; Frézard F; Moore AC
    Int J Pharm; 2020 Aug; 586():119390. PubMed ID: 32540349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
    Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
    Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
    Ravindran R; Maji M; Ali N
    Mol Pharm; 2012 Jan; 9(1):59-70. PubMed ID: 22133194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
    Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
    Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
    Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
    Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-4 contributes to failure, and colludes with IL-10 to exacerbate Leishmania donovani infection following administration of a subcutaneous leishmanial antigen vaccine.
    Bhowmick S; Ravindran R; Ali N
    BMC Microbiol; 2014 Jan; 14():8. PubMed ID: 24428931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiating effects of MPL on DSPC bearing cationic liposomes promote recombinant GP63 vaccine efficacy: high immunogenicity and protection.
    Mazumder S; Maji M; Ali N
    PLoS Negl Trop Dis; 2011 Dec; 5(12):e1429. PubMed ID: 22206029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Med Microbiol Immunol; 2015 Aug; 204(4):539-50. PubMed ID: 25432859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani.
    Bhowmick S; Ravindran R; Ali N
    Infect Immun; 2008 Mar; 76(3):1003-15. PubMed ID: 18195029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmania donovani serine protease encapsulated in liposome elicits protective immunity in experimental visceral leishmaniasis.
    Das P; Paik D; Naskar K; Chakraborti T
    Microbes Infect; 2018 Jan; 20(1):37-47. PubMed ID: 28970116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.
    Jafari I; Heravi Shargh V; Shahryari M; Abbasi A; Jaafari MR; Khamesipour A; Badiee A
    Immunobiology; 2018; 223(6-7):493-500. PubMed ID: 29317110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the immunoprophylactic potential of a killed vaccine candidate in combination with different adjuvants against murine visceral leishmaniasis.
    Thakur A; Kaur H; Kaur S
    Parasitol Int; 2015 Feb; 64(1):70-8. PubMed ID: 25316605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
    Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
    Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
    Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
    Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with antigenic extracts of Leishmania associated with Montanide ISA 763 adjuvant induces partial protection in BALB/c mice against Leishmania (Leishmania) amazonensis infection.
    Cargnelutti DE; Salomón MC; Celedon V; García Bustos MF; Morea G; Cuello-Carrión FD; Scodeller EA
    J Microbiol Immunol Infect; 2016 Feb; 49(1):24-32. PubMed ID: 24662018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of adjuvant activity of fractions derived from Agaricus blazei, when in association with the recombinant LiHyp1 protein, to protect against visceral leishmaniasis.
    de Jesus Pereira NC; Régis WC; Costa LE; de Oliveira JS; da Silva AG; Martins VT; Duarte MC; de Souza JR; Lage PS; Schneider MS; Melo MN; Soto M; Soares SA; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    Exp Parasitol; 2015 Jun; 153():180-90. PubMed ID: 25845753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice.
    Zhang WW; Matlashewski G
    Infect Immun; 2008 Aug; 76(8):3777-83. PubMed ID: 18474642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against murine cutaneous leishmaniasis by using Leishmania major antigen/liposomes. Optimization and assessment of the requirement for intravenous immunization.
    Kahl LP; Scott CA; Lelchuk R; Gregoriadis G; Liew FY
    J Immunol; 1989 Jun; 142(12):4441-9. PubMed ID: 2786033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
    Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
    Front Immunol; 2018; 9():465. PubMed ID: 29599776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.